Document and Entity Information |
Sep. 19, 2023 |
|---|---|
| Cover [Abstract] | |
| Amendment Flag | true |
| Entity Central Index Key | 0001419041 |
| Document Type | 8-K/A |
| Document Period End Date | Sep. 19, 2023 |
| Entity Registrant Name | FORTE BIOSCIENCES, INC. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-38052 |
| Entity Tax Identification Number | 26-1243872 |
| Entity Address, Address Line One | 3060 Pegasus Park Dr. |
| Entity Address, Address Line Two | Building 6 |
| Entity Address, City or Town | Dallas |
| Entity Address, State or Province | TX |
| Entity Address, Postal Zip Code | 75247 |
| City Area Code | (310) |
| Local Phone Number | 618-6994 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, $0.001 par value |
| Trading Symbol | FBRX |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Amendment Description | This Current Report on Form 8-K/A is being filed by Forte Biosciences, Inc. (the “Company”) as a second amendment (the “Second Amendment”) to the Current Report on Form 8-K filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) on September 20, 2023 (the “Original 8-K”), as amended by Amendment No. 1 filed by the Company with the SEC on September 26, 2023 (the “First Amendment”). This Second Amendment is being filed to disclose, in accordance with Item 5.07(d) of Form 8-K, the Company’s decision as to how frequently the Company will include a stockholder advisory vote on the compensation of its named executive officers. Except as described herein, no other changes have been made to the Original 8-K or the First Amendment. |